ID   ST1E1_HUMAN             Reviewed;         294 AA.
AC   P49888; Q8N6X5;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   07-APR-2021, entry version 178.
DE   RecName: Full=Sulfotransferase 1E1;
DE            Short=ST1E1;
DE            EC=2.8.2.4 {ECO:0000269|PubMed:11884392, ECO:0000269|PubMed:7779757};
DE   AltName: Full=EST-1 {ECO:0000303|PubMed:7779757};
DE   AltName: Full=Estrogen sulfotransferase {ECO:0000303|PubMed:8185618};
DE   AltName: Full=Sulfotransferase, estrogen-preferring;
GN   Name=SULT1E1; Synonyms=STE;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8185618; DOI=10.1006/bbrc.1994.1637;
RA   Aksoy I.A., Wood T.C., Weinshilboum R.M.;
RT   "Human liver estrogen sulfotransferase: identification by cDNA cloning and
RT   expression.";
RL   Biochem. Biophys. Res. Commun. 200:1621-1629(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=8530066; DOI=10.1006/geno.1995.1210;
RA   Her C., Aksoy I.A., Kimura S., Brandriff B.F., Wasmuth J.J.,
RA   Weinshilboum R.M.;
RT   "Human estrogen sulfotransferase gene (STE): cloning, structure, and
RT   chromosomal localization.";
RL   Genomics 29:16-23(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, SUBSTRATE SPECIFICITY, AND
RP   FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=7779757; DOI=10.1016/0960-0760(95)00015-r;
RA   Falany C.N., Krasnykh V., Falany J.L.;
RT   "Bacterial expression and characterization of a cDNA for human liver
RT   estrogen sulfotransferase.";
RL   J. Steroid Biochem. Mol. Biol. 52:529-539(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10541560; DOI=10.1093/molehr/5.11.995;
RA   Rubin G.L., Harrold A.J., Mills J.A., Falany C.N., Coughtrie M.W.H.;
RT   "Regulation of sulphotransferase expression in the endometrium during the
RT   menstrual cycle, by oral contraceptives and during early pregnancy.";
RL   Mol. Hum. Reprod. 5:995-1002(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TYR-22.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 182-294.
RC   TISSUE=Liver, and Spleen;
RA   Her C., Szumlanski C., Aksoy I., Weinshilboum R.M.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   MUTAGENESIS OF LYS-85; HIS-107 AND VAL-145, CATALYTIC ACTIVITY, FUNCTION,
RP   SUBCELLULAR LOCATION, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY REGULATION,
RP   AND ACTIVE SITE.
RX   PubMed=11006110; DOI=10.1006/bbrc.2000.3473;
RA   Hempel N., Barnett A.C., Bolton-Grob R.M., Liyou N.E., McManus M.E.;
RT   "Site-directed mutagenesis of the substrate-binding cleft of human estrogen
RT   sulfotransferase.";
RL   Biochem. Biophys. Res. Commun. 276:224-230(2000).
RN   [9]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND FUNCTION.
RX   PubMed=19589875; DOI=10.1124/dmd.108.025759;
RA   Cook I.T., Duniec-Dmuchowski Z., Kocarek T.A., Runge-Morris M.,
RA   Falany C.N.;
RT   "24-hydroxycholesterol sulfation by human cytosolic sulfotransferases:
RT   formation of monosulfates and disulfates, molecular modeling, sulfatase
RT   sensitivity, and inhibition of liver x receptor activation.";
RL   Drug Metab. Dispos. 37:2069-2078(2009).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF MUTANT VAL-269 IN COMPLEX WITH
RP   3'-PHOSPHATE-ADENOSINE-5'-PHOSPHATE SULFATE (PAPS), FUNCTION, CATALYTIC
RP   ACTIVITY, MUTAGENESIS OF SER-137, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   SUBUNIT.
RX   PubMed=11884392; DOI=10.1074/jbc.m111651200;
RA   Pedersen L.C., Petrotchenko E., Shevtsov S., Negishi M.;
RT   "Crystal structure of the human estrogen sulfotransferase-PAPS complex:
RT   evidence for catalytic role of Ser137 in the sulfuryl transfer reaction.";
RL   J. Biol. Chem. 277:17928-17932(2002).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) IN COMPLEX WITH ADENOSINE
RP   3',5'-BISPHOSPHATE (PAP) AND A HYDROXYLATED POLYCHLORINATED BIPHENYL
RP   (OH-PCB).
RX   PubMed=12782487; DOI=10.1289/ehp.6056;
RA   Shevtsov S., Petrotchenko E.V., Pedersen L.C., Negishi M.;
RT   "Crystallographic analysis of a hydroxylated polychlorinated biphenyl (OH-
RT   PCB) bound to the catalytic estrogen binding site of human estrogen
RT   sulfotransferase.";
RL   Environ. Health Perspect. 111:884-888(2003).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate
CC       (PAPS) as sulfonate donor to catalyze the sulfate conjugation of
CC       estradiol and estrone (PubMed:7779757, PubMed:11884392,
CC       PubMed:11006110). Is a key enzyme in estrogen homeostasis, the
CC       sulfation of estrogens leads to their inactivation. Also sulfates
CC       dehydroepiandrosterone (DHEA), pregnenolone, (24S)-hydroxycholesterol
CC       and xenobiotic compounds like ethinylestradiol, equalenin, diethyl
CC       stilbesterol and 1-naphthol at significantly lower efficiency
CC       (PubMed:11006110, PubMed:19589875). Does not sulfonate cortisol,
CC       testosterone and dopamine (PubMed:7779757, PubMed:11006110).
CC       {ECO:0000269|PubMed:11006110, ECO:0000269|PubMed:11884392,
CC       ECO:0000269|PubMed:19589875, ECO:0000269|PubMed:7779757}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + estrone = adenosine 3',5'-
CC         bisphosphate + estrone 3-sulfate + H(+); Xref=Rhea:RHEA:15973,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:17263, ChEBI:CHEBI:58339,
CC         ChEBI:CHEBI:58343, ChEBI:CHEBI:60050; EC=2.8.2.4;
CC         Evidence={ECO:0000269|PubMed:11006110, ECO:0000269|PubMed:11884392,
CC         ECO:0000269|PubMed:7779757};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15974;
CC         Evidence={ECO:0000305|PubMed:11884392};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(24S)-hydroxycholesterol + 3'-phosphoadenylyl sulfate = (24S)-
CC         hydroxycholesterol 3-sulfate + adenosine 3',5'-bisphosphate + H(+);
CC         Xref=Rhea:RHEA:52348, ChEBI:CHEBI:15378, ChEBI:CHEBI:34310,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136567;
CC         Evidence={ECO:0000269|PubMed:19589875};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52349;
CC         Evidence={ECO:0000305|PubMed:19589875};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + 3'-phosphoadenylyl sulfate = 17beta-
CC         estradiol 3-sulfate + adenosine 3',5'-bisphosphate + H(+);
CC         Xref=Rhea:RHEA:52372, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:58339, ChEBI:CHEBI:58343, ChEBI:CHEBI:136582;
CC         Evidence={ECO:0000269|PubMed:11006110, ECO:0000269|PubMed:7779757};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52373;
CC         Evidence={ECO:0000305|PubMed:7779757};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3'-phosphoadenylyl sulfate + 3beta-hydroxyandrost-5-en-17-one
CC         = 3beta-sulfooxy-androst-5-en-17-one + adenosine 3',5'-bisphosphate +
CC         H(+); Xref=Rhea:RHEA:51216, ChEBI:CHEBI:15378, ChEBI:CHEBI:28689,
CC         ChEBI:CHEBI:57905, ChEBI:CHEBI:58339, ChEBI:CHEBI:58343;
CC         Evidence={ECO:0000269|PubMed:11006110};
CC   -!- ACTIVITY REGULATION: Inhibited by estradiol.
CC       {ECO:0000269|PubMed:11006110}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.3 uM for 17beta-estradiol {ECO:0000269|PubMed:11006110};
CC         KM=0.2 uM for estrone {ECO:0000269|PubMed:11006110};
CC         KM=0.2 uM for DHEA {ECO:0000269|PubMed:11006110};
CC         KM=32220 uM for dopamine {ECO:0000269|PubMed:11006110};
CC         KM=76.6 uM for p-nitrophenol {ECO:0000269|PubMed:11006110};
CC         KM=0.9 uM for (24S)-hydroxycholesterol {ECO:0000269|PubMed:19589875};
CC         KM=0.66 uM for PAPS {ECO:0000269|PubMed:11884392};
CC         KM=0.46 uM for PAPS {ECO:0000269|PubMed:11006110};
CC         Vmax=37.2 nmol/min/mg enzyme with 17beta-estradiol
CC         {ECO:0000269|PubMed:11006110};
CC         Vmax=16.3 nmol/min/mg enzyme with estrone
CC         {ECO:0000269|PubMed:11006110};
CC         Vmax=5.5 nmol/min/mg enzyme with DHEA {ECO:0000269|PubMed:11006110};
CC         Vmax=13.3 nmol/min/mg enzyme with dopaminne;
CC         Vmax=135.9 nmol/min/mg enzyme with p-nitrophenol
CC         {ECO:0000269|PubMed:11006110};
CC         Note=Kcat is 55 min(-1) with (24S)-hydroxycholesterol.
CC         {ECO:0000269|PubMed:19589875};
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:11884392,
CC       ECO:0000269|PubMed:12782487}.
CC   -!- INTERACTION:
CC       P49888; O76083: PDE9A; NbExp=3; IntAct=EBI-712512, EBI-742764;
CC       P49888; O76083-2: PDE9A; NbExp=3; IntAct=EBI-712512, EBI-11524542;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11006110}.
CC   -!- TISSUE SPECIFICITY: Liver, intestine and at lower level in the kidney.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ste/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U08098; AAA82125.1; -; mRNA.
DR   EMBL; U20521; AAC50286.1; -; Genomic_DNA.
DR   EMBL; U20515; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; U20516; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; U20517; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; U20518; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; U20519; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; U20520; AAC50286.1; JOINED; Genomic_DNA.
DR   EMBL; S77383; AAB34601.1; -; mRNA.
DR   EMBL; Y11195; CAA72079.1; -; mRNA.
DR   EMBL; AY436634; AAQ97179.1; -; Genomic_DNA.
DR   EMBL; BC027956; AAH27956.1; -; mRNA.
DR   EMBL; U55764; AAB51658.1; -; mRNA.
DR   CCDS; CCDS3531.1; -.
DR   PIR; JC2229; JC2229.
DR   RefSeq; NP_005411.1; NM_005420.2.
DR   PDB; 1G3M; X-ray; 1.70 A; A/B=1-294.
DR   PDB; 1HY3; X-ray; 1.80 A; A/B=1-294.
DR   PDB; 4JVL; X-ray; 1.94 A; A/B=1-294.
DR   PDB; 4JVM; X-ray; 1.99 A; A/B=1-294.
DR   PDB; 4JVN; X-ray; 2.05 A; A/B=1-294.
DR   PDBsum; 1G3M; -.
DR   PDBsum; 1HY3; -.
DR   PDBsum; 4JVL; -.
DR   PDBsum; 4JVM; -.
DR   PDBsum; 4JVN; -.
DR   SMR; P49888; -.
DR   BioGRID; 112660; 14.
DR   IntAct; P49888; 12.
DR   STRING; 9606.ENSP00000226444; -.
DR   BindingDB; P49888; -.
DR   ChEMBL; CHEMBL2346; -.
DR   DrugBank; DB02902; 3'-phospho-5'-adenylyl sulfate.
DR   DrugBank; DB03346; 3,3',5,5'-tetrachlorobiphenyl-4,4'-diol.
DR   DrugBank; DB01812; Adenosine 3',5'-diphosphate.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB14635; Curcumin sulfate.
DR   DrugBank; DB01176; Cyclizine.
DR   DrugBank; DB00977; Ethinylestradiol.
DR   DrugBank; DB09288; Propacetamol.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB09100; Thyroid, porcine.
DR   SwissLipids; SLP:000001693; -.
DR   iPTMnet; P49888; -.
DR   PhosphoSitePlus; P49888; -.
DR   BioMuta; SULT1E1; -.
DR   DMDM; 1711604; -.
DR   EPD; P49888; -.
DR   MassIVE; P49888; -.
DR   PaxDb; P49888; -.
DR   PeptideAtlas; P49888; -.
DR   PRIDE; P49888; -.
DR   ProteomicsDB; 56163; -.
DR   Antibodypedia; 24249; 286 antibodies.
DR   CPTC; P49888; 3 antibodies.
DR   Ensembl; ENST00000226444; ENSP00000226444; ENSG00000109193.
DR   GeneID; 6783; -.
DR   KEGG; hsa:6783; -.
DR   CTD; 6783; -.
DR   DisGeNET; 6783; -.
DR   GeneCards; SULT1E1; -.
DR   HGNC; HGNC:11377; SULT1E1.
DR   HPA; ENSG00000109193; Tissue enhanced (intestine, liver, vagina).
DR   MIM; 600043; gene.
DR   neXtProt; NX_P49888; -.
DR   OpenTargets; ENSG00000109193; -.
DR   PharmGKB; PA340; -.
DR   VEuPathDB; HostDB:ENSG00000109193.10; -.
DR   eggNOG; KOG1584; Eukaryota.
DR   GeneTree; ENSGT00940000162261; -.
DR   HOGENOM; CLU_027239_1_2_1; -.
DR   InParanoid; P49888; -.
DR   OMA; IPYLECR; -.
DR   OrthoDB; 780670at2759; -.
DR   PhylomeDB; P49888; -.
DR   TreeFam; TF321745; -.
DR   BRENDA; 2.8.2.4; 2681.
DR   PathwayCommons; P49888; -.
DR   Reactome; R-HSA-156584; Cytosolic sulfonation of small molecules.
DR   SABIO-RK; P49888; -.
DR   SIGNOR; P49888; -.
DR   BioGRID-ORCS; 6783; 73 hits in 996 CRISPR screens.
DR   EvolutionaryTrace; P49888; -.
DR   GeneWiki; SULT1E1; -.
DR   GenomeRNAi; 6783; -.
DR   Pharos; P49888; Tchem.
DR   PRO; PR:P49888; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P49888; protein.
DR   Bgee; ENSG00000109193; Expressed in kidney and 122 other tissues.
DR   ExpressionAtlas; P49888; baseline and differential.
DR   Genevisible; P49888; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0004062; F:aryl sulfotransferase activity; IBA:GO_Central.
DR   GO; GO:0004304; F:estrone sulfotransferase activity; TAS:ProtInc.
DR   GO; GO:0047894; F:flavonol 3-sulfotransferase activity; IDA:BHF-UCL.
DR   GO; GO:0005496; F:steroid binding; IEA:UniProtKB-KW.
DR   GO; GO:0050294; F:steroid sulfotransferase activity; IDA:UniProtKB.
DR   GO; GO:0008146; F:sulfotransferase activity; IDA:MGI.
DR   GO; GO:0050427; P:3'-phosphoadenosine 5'-phosphosulfate metabolic process; IDA:CAFA.
DR   GO; GO:0006711; P:estrogen catabolic process; IDA:CAFA.
DR   GO; GO:0008210; P:estrogen metabolic process; IDA:UniProtKB.
DR   GO; GO:0006068; P:ethanol catabolic process; IDA:CAFA.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IMP:CACAO.
DR   GO; GO:0008202; P:steroid metabolic process; TAS:ProtInc.
DR   GO; GO:0051923; P:sulfation; IDA:BHF-UCL.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Lipid-binding; Reference proteome;
KW   Steroid-binding; Transferase.
FT   CHAIN           1..294
FT                   /note="Sulfotransferase 1E1"
FT                   /id="PRO_0000085153"
FT   NP_BIND         47..52
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   NP_BIND         226..231
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   NP_BIND         256..258
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   REGION          105..107
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   ACT_SITE        107
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000269|PubMed:11006110"
FT   BINDING         129
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   BINDING         137
FT                   /note="PAPS"
FT                   /evidence="ECO:0000269|PubMed:11884392"
FT   BINDING         192
FT                   /note="PAPS"
FT                   /evidence="ECO:0000250|UniProtKB:P49891"
FT   VARIANT         22
FT                   /note="D -> Y (in dbSNP:rs11569705)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_018907"
FT   MUTAGEN         85
FT                   /note="K->A: Does not have decreased sulfonation activity
FT                   towards the estrogens and DHEA."
FT                   /evidence="ECO:0000269|PubMed:11006110"
FT   MUTAGEN         107
FT                   /note="H->A: Complete loss of sulfonation activity towards
FT                   all substrates tested."
FT                   /evidence="ECO:0000269|PubMed:11006110"
FT   MUTAGEN         137
FT                   /note="S->A: Decreased gradually the sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11884392"
FT   MUTAGEN         137
FT                   /note="S->C: Decreased gradually the sulfotransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:11884392"
FT   MUTAGEN         145
FT                   /note="V->E: Substrate specificity constants for estradiol
FT                   and estrone are reduced. Dramatic 400-fold increase in the
FT                   ability to sulfonate dopamine."
FT                   /evidence="ECO:0000269|PubMed:11006110"
FT   MUTAGEN         269
FT                   /note="V->E: Does not prevent the formation of homodimer."
FT                   /evidence="ECO:0000269|PubMed:11884392"
FT   CONFLICT        154
FT                   /note="F -> L (in Ref. 6; AAH27956)"
FT                   /evidence="ECO:0000305"
FT   HELIX           4..10
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          11..14
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          17..20
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           21..25
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           27..31
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          40..45
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           50..61
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   TURN            62..64
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           66..69
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          70..72
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           74..77
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   TURN            86..88
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           91..96
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          103..106
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           110..112
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           115..119
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          123..128
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           131..144
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           154..162
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           171..181
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   STRAND          187..191
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           192..197
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           199..209
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           216..225
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           228..233
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   TURN            235..237
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   TURN            244..246
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   TURN            249..251
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           262..265
FT                   /evidence="ECO:0007744|PDB:1G3M"
FT   HELIX           269..283
FT                   /evidence="ECO:0007744|PDB:1G3M"
SQ   SEQUENCE   294 AA;  35126 MW;  9EC8923D20757D57 CRC64;
     MNSELDYYEK FEEVHGILMY KDFVKYWDNV EAFQARPDDL VIATYPKSGT TWVSEIVYMI
     YKEGDVEKCK EDVIFNRIPF LECRKENLMN GVKQLDEMNS PRIVKTHLPP ELLPASFWEK
     DCKIIYLCRN AKDVAVSFYY FFLMVAGHPN PGSFPEFVEK FMQGQVPYGS WYKHVKSWWE
     KGKSPRVLFL FYEDLKEDIR KEVIKLIHFL ERKPSEELVD RIIHHTSFQE MKNNPSTNYT
     TLPDEIMNQK LSPFMRKGIT GDWKNHFTVA LNEKFDKHYE QQMKESTLKF RTEI
//
